Can Chronic Gastritis Cause an Increase in Fecal Calprotectin Concentrations?

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2010 Jul 16

PMID 20632443

Citations 9

Authors

Massimo Montalto

Antonella Gallo

Gianluca Ianiro

Luca Santoro

Ferruccio DOnofrio

Riccardo Ricci

Giovanni Cammarota

Marcello Covino

Monica Vastola

Antonio Gasbarrini

Giovanni Gasbarrini

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate fecal calprotectin concentrations (FCCs) in subjects with chronic gastritis and the correlation between FCCs and gastritis activity score.

Methods: FCCs were measured in 61 patients with histological diagnosis of gastritis and in 74 healthy volunteers. Histological grading of gastritis was performed according to the updated Sydney gastritis classification. Patients were subdivided into 2 groups according to the presence/absence of an active gastritis. Patients with chronic active gastritis were divided into 3 subgroups on the basis of the activity score (mild, moderate, marked). FFCs in relation to Helicobacter pylori (H. pylori) infection and proton pump inhibitor (PPI) use were also evaluated.

Results: FCCs in patients with chronic active gastritis were not significantly different to FCCs either in subjects with non active gastritis or in healthy controls. Among patients with chronic active gastritis (even marked), FCCs did not significantly differ according to activity score. No significant differences in FCCs were found when considering H. pylori, as well as when considering PPI chronic use.

Conclusion: FCCs were not significantly increased in subjects with chronic gastritis, even in those patients with a marked neutrophil infiltration.

Citing Articles

Diagnostic Value of Fecal Calprotectin in Children with Gastritis, Duodenitis and Helicobacter Pylori.

Rafeey M, Nikmanesh P, Javadzadeh F Int J Prev Med. 2022; 13:107.

PMID: 36247193 PMC: 9564235. DOI: 10.4103/ijpvm.IJPVM_507_20.

Fecal calprotectin levels used as a noninvasive method for screening for chronic gastritis in pediatric patients. A descriptive study.

Demirbas F, Caltepe G, Abbasguliyev H, Kalayci A Sao Paulo Med J. 2021; 139(6):564-569.

PMID: 34406311 PMC: 9634843. DOI: 10.1590/1516-3180.2020.0765.R1.0904221.

Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch-Schönlein purpura patients: a retrospective analysis.

Paek E, Yi D, Kang B, Choe B BMC Pediatr. 2020; 20(1):374.

PMID: 32770991 PMC: 7414667. DOI: 10.1186/s12887-020-02263-x.

Probiotics-Containing Yogurt Ingestion and Eradication Can Restore Fecal Dysbiosis in -Infected Children.

Yang Y, Chen P, Lai F, Tsai P, Sheu B Biomedicines. 2020; 8(6).

PMID: 32492860 PMC: 7344718. DOI: 10.3390/biomedicines8060146.

Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use.

Aalto K, Lahdenne P, Kolho K Pediatr Rheumatol Online J. 2017; 15(1):9.

PMID: 28143478 PMC: 5286851. DOI: 10.1186/s12969-016-0132-2.

References

Fagerberg U, Loof L, Lindholm J, Hansson L, Finkel Y . Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 45(4):414-20. DOI: 10.1097/MPG.0b013e31810e75a9. View

Costa F, Mumolo M, Bellini M, Romano M, Ceccarelli L, Arpe P . Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003; 35(9):642-7. DOI: 10.1016/s1590-8658(03)00381-5. View

Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S . A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000; 47(4):506-13. PMC: 1728060. DOI: 10.1136/gut.47.4.506. View

Roseth A, Fagerhol M, Aadland E, Schjonsby H . Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992; 27(9):793-8. DOI: 10.3109/00365529209011186. View

Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A . Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004; 96(22):1702-13. DOI: 10.1093/jnci/djh305. View

Price A . The Sydney System: histological division. J Gastroenterol Hepatol. 1991; 6(3):209-22. DOI: 10.1111/j.1440-1746.1991.tb01468.x. View

Kedika R, Souza R, Spechler S . Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009; 54(11):2312-7. PMC: 3035917. DOI: 10.1007/s10620-009-0951-9. View

von Roon A, Karamountzos L, Purkayastha S, Reese G, Darzi A, Teare J . Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102(4):803-13. DOI: 10.1111/j.1572-0241.2007.01126.x. View

Stolte M, Eidt S . Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis. Z Gastroenterol. 1992; 30(12):846-50. View

10.

Bjerke K, Halstensen T, Jahnsen F, Pulford K, Brandtzaeg P . Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut. 1993; 34(10):1357-63. PMC: 1374541. DOI: 10.1136/gut.34.10.1357. View

11.

Sipponen T, Karkkainen P, Savilahti E, Kolho K, Nuutinen H, Turunen U . Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008; 28(10):1221-9. DOI: 10.1111/j.1365-2036.2008.03835.x. View

12.

Poullis A, Foster R, Mendall M, Fagerhol M . Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003; 18(7):756-62. DOI: 10.1046/j.1440-1746.2003.03014.x. View

13.

Vermeire S, Van Assche G, Rutgeerts P . Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006; 55(3):426-31. PMC: 1856093. DOI: 10.1136/gut.2005.069476. View

14.

Dixon M, Genta R, Yardley J, Correa P . Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996; 20(10):1161-81. DOI: 10.1097/00000478-199610000-00001. View

15.

Montalto M, Curigliano V, Santoro L, Armuzzi A, Cammarota G, Covino M . Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol. 2006; 102(1):132-6. DOI: 10.1111/j.1572-0241.2006.00884.x. View

16.

Gisbert J, Bermejo F, Perez-Calle J, Taxonera C, Vera I, McNicholl A . Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009; 15(8):1190-8. DOI: 10.1002/ibd.20933. View

17.

Summerton C, Longlands M, Wiener K, Shreeve D . Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002; 14(8):841-5. DOI: 10.1097/00042737-200208000-00005. View

18.

Gisbert J, McNicholl A . Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2008; 41(1):56-66. DOI: 10.1016/j.dld.2008.05.008. View

19.

Bar-Gil Shitrit A, Braverman D, Stankiewics H, Shitrit D, Peled N, Paz K . Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum. 2007; 50(12):2188-93. DOI: 10.1007/s10350-007-9038-x. View

20.

Tibble J, Sigthorsson G, Bridger S, Fagerhol M, Bjarnason I . Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119(1):15-22. DOI: 10.1053/gast.2000.8523. View